PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Brain Behavior & Immunity - Health0 citationsOpen Access

Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study

View Full Paper
CKChristina N. KushnirVTVictoria Taylor-BatemanNDNeil M Davies

Key Points

  • FCGR3B shows a causal effect on Alzheimer's disease risk, linking it to potential therapies.
  • The analysis identified FCGR3B as a significant target, while others were not shown to influence risk.
  • Mendelian randomization was employed to assess the relationship between DMARD targets and Alzheimer's disease.
  • Further research is necessary to understand FCGR3B's role and validate its therapeutic potential.

Abstract

Our findings suggest a causal effect of FCGR3B on AD risk, but not for the remainder of the analyzed DMARD targets. Further research is recommended to elucidate the causal role of FCGR3B in AD and build upon the current literature on viable AD therapeutic targets.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kushnir et al. (2026) studied this question.

synapsesocial.com/papers/69a75f68c6e9836116a2ac06https://doi.org/10.1016/j.bbih.2026.101185
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tissue specificity and the human protein interaction network2009 · 326 citations
  2. 2Etanercept in Alzheimer disease2015 · 250 citations
  3. 3Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 20192022 · 5,500 citations
  4. 4A Meta-Analysis of Cytokines in Alzheimer's Disease2010 · 1,118 citations
  5. 5Drug target Mendelian randomisation: are we really instrumenting drug use?2023 · 17 citations